Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

NCT00489905 is registered in ClinicalTrials.gov with Hospital Authority, Hong Kong as lead sponsor.

NCT NCT00489905
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00489905 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
Lead sponsor
Hospital Authority, Hong Kong
Phase
Not applicable
Overall status
Completed
Start date
April 30, 2005
Completion date
May 31, 2008
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bone density, prostatic neoplasms